Literature DB >> 34966954

Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy.

Yanting Duan1,2,3, Ruoqi Chen1,2,3, Yanjie Huang4, Xianhui Meng1,2,3, Jiangqing Chen1,2,3, Chan Liao5, Yongmin Tang5, Chun Zhou6, Xiaofei Gao4, Jie Sun7,8,9.   

Abstract

How single-chain variable fragments (scFvs) affect the functions of chimeric antigen receptors (CARs) has not been well studied. Here, the components of CAR with an emphasis on scFv were described, and then several methods to measure scFv affinity were discussed. Next, scFv optimization studies for CD19, CD38, HER2, GD2 or EGFR were overviewed, showing that tuning the affinity of scFv could alleviate the on-target/off-tumor toxicity. The affinities of scFvs for different antigens were also summarized to designate a relatively optimal working range for CAR design. Last, a synthetic biology approach utilizing a low-affinity synthetic Notch (synNotch) receptor to achieve ultrasensitivity of antigen-density discrimination and murine models to assay the on-target/off-tumor toxicity of CARs were highlighted. Thus, this review provides preliminary guidelines of choosing the right scFvs for CARs.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Adoptive cell therapy; Affinity; Chimeric antigen receptor; Immunotherapy; On-target/off-tumor; scFv

Mesh:

Substances:

Year:  2021        PMID: 34966954     DOI: 10.1007/s00018-021-04089-x

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  65 in total

1.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors:  Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

2.  Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Authors:  Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

Review 3.  Chimeric Antigen Receptor Therapy.

Authors:  Carl H June; Michel Sadelain
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

4.  KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

Authors:  Michael Wang; Javier Munoz; Andre Goy; Frederick L Locke; Caron A Jacobson; Brian T Hill; John M Timmerman; Houston Holmes; Samantha Jaglowski; Ian W Flinn; Peter A McSweeney; David B Miklos; John M Pagel; Marie-Jose Kersten; Noel Milpied; Henry Fung; Max S Topp; Roch Houot; Amer Beitinjaneh; Weimin Peng; Lianqing Zheng; John M Rossi; Rajul K Jain; Arati V Rao; Patrick M Reagan
Journal:  N Engl J Med       Date:  2020-04-02       Impact factor: 91.245

Review 5.  Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.

Authors:  M-L Schubert; M Schmitt; L Wang; C A Ramos; K Jordan; C Müller-Tidow; P Dreger
Journal:  Ann Oncol       Date:  2020-10-21       Impact factor: 32.976

Review 6.  Managing cytokine release syndrome associated with novel T cell-engaging therapies.

Authors:  Shannon L Maude; David Barrett; David T Teachey; Stephan A Grupp
Journal:  Cancer J       Date:  2014 Mar-Apr       Impact factor: 3.360

7.  Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.

Authors:  Frederick L Locke; Sattva S Neelapu; Nancy L Bartlett; Tanya Siddiqi; Julio C Chavez; Chitra M Hosing; Armin Ghobadi; Lihua E Budde; Adrian Bot; John M Rossi; Yizhou Jiang; Allen X Xue; Meg Elias; Jeff Aycock; Jeff Wiezorek; William Y Go
Journal:  Mol Ther       Date:  2017-01-04       Impact factor: 11.454

Review 8.  Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.

Authors:  Shengnan Yu; Ming Yi; Shuang Qin; Kongming Wu
Journal:  Mol Cancer       Date:  2019-08-20       Impact factor: 27.401

Review 9.  CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors.

Authors:  Anna C Filley; Mario Henriquez; Mahua Dey
Journal:  Front Oncol       Date:  2018-10-17       Impact factor: 6.244

10.  Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.

Authors:  Jim S Qin; Timothy G Johnstone; Alex Baturevych; Ronald J Hause; Seamus P Ragan; Christopher R Clouser; Jon C Jones; Rafael Ponce; Cecile M Krejsa; Ruth A Salmon; Michael O Ports
Journal:  J Immunother       Date:  2020-05       Impact factor: 4.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.